Skip to content

Acorda Therapeutics, Inc.: 10-Q filed 2011-11-07

What Acorda Therapeutics, Inc. reported in its quarterly report filed 2011-11-07 (fiscal Q3 2011): 35 published measures, 98 facts as tagged in accession 0001008848-11-000082.

This filing

Form
10-Q (quarterly report)
Filed
2011-11-07
Fiscal period
fiscal Q3 2011
Accession
0001008848-11-000082 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Acorda Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-09-30351,098,000USD
At 2010-12-31342,101,000USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-09-30186,916,000USD
At 2010-12-31151,261,000USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2011-09-3044,385,000USD
At 2010-12-3134,641,000USD
At 2010-09-3082,405,000USD
At 2009-12-3147,314,000USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-07-01 to 2011-09-3018,867,000USD92
2011-01-01 to 2011-09-3017,911,000USD273
2010-07-01 to 2010-09-3012,438,000USD92
2010-01-01 to 2010-09-30-15,440,000USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-01-01 to 2011-09-3033,366,000USD273
2010-01-01 to 2010-09-30-20,803,000USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2011-01-01 to 2011-09-301,232,000USD273
2010-01-01 to 2010-09-302,207,000USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-01-01 to 2011-09-302,462,000USD273
2010-01-01 to 2010-09-306,607,000USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2011-01-01 to 2011-09-30-26,084,000USD273
2010-01-01 to 2010-09-3049,287,000USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2011-09-30-422,175,000USD
At 2010-12-31-440,086,000USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2011-07-01 to 2011-09-3039,100shares92
2011-01-01 to 2011-09-3038,940shares273
2010-07-01 to 2010-09-3038,450shares92
2010-01-01 to 2010-09-3038,261shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2011-07-01 to 2011-09-3040,174shares92
2011-01-01 to 2011-09-3040,035shares273
2010-07-01 to 2010-09-3039,988shares92
2010-01-01 to 2010-09-3038,261shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2011-07-01 to 2011-09-300.48USD/shares92
2011-01-01 to 2011-09-300.46USD/shares273
2010-07-01 to 2010-09-300.32USD/shares92
2010-01-01 to 2010-09-30-0.4USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2011-07-01 to 2011-09-300.47USD/shares92
2011-01-01 to 2011-09-300.45USD/shares273
2010-07-01 to 2010-09-300.31USD/shares92
2010-01-01 to 2010-09-30-0.4USD/shares273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2011-07-01 to 2011-09-30986,000USD92
2011-01-01 to 2011-09-301,165,000USD273
2010-07-01 to 2010-09-300USD92
2010-01-01 to 2010-09-300USD273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2011-09-303,595,000USD
At 2010-12-313,203,000USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2011-07-01 to 2011-09-305,100,000USD92
2011-01-01 to 2011-09-3013,847,000USD273
2010-07-01 to 2010-09-304,800,000USD92
2010-01-01 to 2010-09-3012,557,000USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-07-01 to 2011-09-3020,666,000USD92
2011-01-01 to 2011-09-3022,027,000USD273
2010-07-01 to 2010-09-3013,263,000USD92
2010-01-01 to 2010-09-30-12,546,000USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-09-30334,373,000USD
At 2010-12-31311,169,000USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2011-07-01 to 2011-09-30947,000USD92
2011-01-01 to 2011-09-303,359,000USD273
2010-07-01 to 2010-09-30944,000USD92
2010-01-01 to 2010-09-303,352,000USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2011-09-3074,437,000USD
At 2010-12-3193,896,000USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2011-09-3013,943,000USD
At 2010-12-3116,961,000USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2011-09-3020,608,000USD
At 2010-12-3122,272,000USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-07-01 to 2011-09-3072,365,000USD92
2011-01-01 to 2011-09-30197,566,000USD273
2010-07-01 to 2010-09-3050,359,000USD92
2010-01-01 to 2010-09-30136,751,000USD273

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2011-07-01 to 2011-09-3034,718,000USD92
2011-01-01 to 2011-09-30112,788,000USD273
2010-07-01 to 2010-09-3030,558,000USD92
2010-01-01 to 2010-09-3091,054,000USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2011-07-01 to 2011-09-309,088,000USD92
2011-01-01 to 2011-09-3031,804,000USD273
2010-07-01 to 2010-09-307,970,000USD92
2010-01-01 to 2010-09-3022,628,000USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2011-09-3039,121,293shares
At 2010-12-3138,779,370shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2011-09-3069,000USD
At 2010-12-31-13,000USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2011-09-307,053,000USD
At 2010-12-3121,336,000USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2011-09-30477,000USD
At 2010-12-31343,000USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2011-09-30480,000USD
At 2010-12-31353,000USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2011-09-3019,239,000USD
At 2010-12-3133,769,000USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2011-09-30148,700,000USD
At 2010-12-31153,800,000USD

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2011-01-01 to 2011-09-303,208,000USD273
2010-01-01 to 2010-09-302,818,000USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2011-07-01 to 2011-09-30-813,000USD92
2011-01-01 to 2011-09-30-2,951,000USD273
2010-07-01 to 2010-09-30-825,000USD92
2010-01-01 to 2010-09-30-2,894,000USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-09-30-1,664,000USD273
2010-01-01 to 2010-09-3012,490,000USD273

Inspect the source

Entity
Acorda Therapeutics, Inc. / CIK 0001008848
Captured
SEC response SHA-256
c2d58bfc837ef6a6ec03ace43e8d0507ad0968fa8666de37eb863e1308c9b0d4

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001008848.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))